After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...

Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $117.39. The firm’s 50 day moving average is $99.15 and its 200-day moving average is $91.09.

Correspondence to Dr. Rish K Pai, Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona 85259, USA; pai.rish{at}mayo.edu The Robarts Histopathology Index (RHI) is a ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need.

Kennet Brysting, president of Gilead Sciences Japan, mentioned an intriguing possibility during an interview in Tokyo late last year. “I do believe that Japan could be one of the first countries ...

The latest analyst rating for Gilead Sciences (NASDAQ:GILD) was provided by Morgan Stanley, and Gilead Sciences maintained their overweight rating. The last upgrade for Gilead Sciences Inc ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...

NEW YORK, March 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's ...